Know Cancer

or
forgot password

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol


N/A
18 Years
N/A
Not Enrolling
Both
Solid Tumors

Thank you

Trial Information

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol


Inclusion Criteria:



- Prior SU011248 Protocol.

- Eligible to continue SU011248 treatment.

Exclusion Criteria:

- Uncontrolled CNS metastasis.

- Unfit to receive SU011248.

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Duration of Treatment

Outcome Time Frame:

Baseline up to Day 28 after last dose of study treatment

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A6181030

NCT ID:

NCT00798889

Start Date:

March 2004

Completion Date:

December 2011

Related Keywords:

  • Solid Tumors
  • Solid tumors

Name

Location

Pfizer Investigational Site Birmingham, Alabama  35205
Pfizer Investigational Site Blendora, California  91740
Pfizer Investigational Site Detroit, Michigan  48201
Pfizer Investigational Site Rochester, Minnesota  55905
Pfizer Investigational Site Cincinnait, Ohio  45236
Pfizer Investigational Site Bronx, New York  10461
Pfizer Investigational Site Houston, Texas  77030
Pfizer Investigational Site Aurora, Colorado  80012
Pfizer Investigational Site Carmel, Indiana  46032
Pfizer Investigational Site North Adams, Massachusetts  01247
Pfizer Investigational Site Columbia, Missouri  65201
Pfizer Investigational Site Santa Fe, New Mexico  87505
Pfizer Investigational Site Asheville, North Carolina  28801
Pfizer Investigational Site Kingston, Pennsylvania  18704-5535
Pfizer Investigational Site Easley,, South Carolina  29640
Pfizer Investigational Site Milwaukee, Wisconsin  53215
Pfizer Investigational Site Bristol, Tennessee  37620